Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended March 31 - Earnings Summary

• Sonnet Biotherapeutics Holdings Inc SONN.OQ reported a quarterly adjusted loss of 89 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of 56 cents. The lone analyst forecast for the quarter was for a loss of 92 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Sonnet Biotherapeutics Holdings Inc's reported EPS for the quarter was a loss of 89 cents​.

• Sonnet Biotherapeutics Holdings Inc shares had fallen by 8.2% this quarter and lost 15.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 16.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Sonnet Biotherapeutics Holdings Inc is $20.00

This summary was machine generated from LSEG data May 16 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)